Recent advances in the prophylaxis and treatment of malaria

Current Infectious Disease Reports

Volumn 3, Issue 1, 2001, Pages 68-76

  Labbé, Annie Claude ^a   Loutfy, Mona R ^a   Kain, Kevin C ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Artesunate; Falciparum Malaria; Malaria; Mefloquine; Vivax Malaria

Indexed keywords

EID: 85084849417     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-001-0061-0     Document Type: Article

References (67)

1. World Health Organization: The world health report 1999: Making a difference. Geneva: World Health Organization; 1999.
2. Croft AMJ, Garner P: Mefloquine for preventing malaria in nonimmune adult travellers [review]. In The Cochrane Library vol 4, iss 1. Oxford: Update Software; 2000. Available on line at: http://www.update-software.com/cochrane/.
3. Committee to advise on tropical medicine and travel (CATMAT): Canadian recommendations for the prevention and treatment of malaria among international travellers. Can Commun Dis Rep 2000, 26(Suppl2). Available on line at: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/ 00vol26/26s2/.
4. World Health Organization: International Travel and Health. Vaccination requirements and health advice 2000. Geneva: World Health Organization; 2000.
5. Centers for Disease Control and Prevention: Health information for international travel 1999–2000, DHHS, Atlanta, GA, 1999.
6. Kain KC: Prophylactic drugs for malaria: why do we need another one? J Travel Med 1999, 6:S2-S7.
7. Bradley DJ, Warhurst DC: Guidelines for the prevention of malaria in travellers from the United Kingdom. PHLS Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine. Bur 1997, 7:R137-R152.
8. Ryan ET, Kain KC: Health advice and immunizations for travellers. N Engl J Med 2000, 342:1716–1725. This is a concise but complete update on travel medicine and malaria prevention.
9. Alecrim WD, Espinosa FE, Alecrim MG: Plasmodium falciparum infection in the pregnant patient. Infect Dis Clin North Am 2000, 14:83–95.
10. Fischer PR: Travel with infants and children. Infect Dis Clin North Am 1998, 12:355–368.
11. Schlagenhauf P: Mefloquine for malaria chemoprophylaxis 1992–1998: a review. J Travel Med 1999, 6:122–133. This excellent comprehensive review of mefloquine for malaria prophylaxis addresses pharmacokinetic data, the controversy regarding tolerability, the evidence regarding use of mefloquine in pregnancy and efficacy studies.
12. Fry M, Pudney M: Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992, 43:1545–1553.
13. Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad-spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997, 272:3961–3966.
14. Pudney M, Gutteridge W, Zeman A, et al.: Atovaquone and proguanil hydrochloride: a review of nonclinical studies. J Travel Med 1999, 6:S8-S12. This is a detailed review of mechanisms of action and pharmackinetic data.
15. Srivastava IK, Vaidya AB: A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999, 43:1334–1339.
16. Looareesuwan S, Viravan C, Webster HK, et al.: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62–66.
17. Helsby NA, Ward SA, Edwards G, et al.: The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990, 30:593–598.
18. Gay F, Bustos D, Traore B: In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 1997, 56:315–317.
19. Srivastava IK, Morrisey JM, Darrouzet E, et al.: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999, 33:704–711.
20. Reynolds MG, Roos DS: A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J Biol Chem 1998, 273:3461–3469.
21. Shapiro TA, Ranasinha CD, Kumar N, et al.: Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999, 60:831–836.
22. Shanks GD, Gordon DM, Klotz FW, et al.: Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998, 27:494–499.
23. Sukwa TY, Mulenga M, Chisdaka N, et al.: A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999, 60:521–525.
24. Lell B, Luckner D, Ndjave M, et al.: Randomised placebocontrolled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998, 351:709–713.
25. Shanks GD, Kremser PG, Sukwa TY, et al.: Atovaquone and proguanil hydrchloride for prophylaxis of malaria. J Travel Med 1999, 6:S21-S27. The authors discuss the atovaquone and proguanil studies for prophylaxis of malaria, and have combined and analyzed together the three randomized, controlled studies in Africa. These studies clearly demonstrate the high efficacy of atovaquone-proguanil for falciparum malaria prophylaxis in semi-immune populations.
26. Fryauff DJ, Baird JK, Basri H, et al.: Randomised placebocontrolled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995, 346:1190–1193.
27. Soto J, Toledo J, Rodriquez M, et al.: Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 129:241–244.
28. Soto J, Toledo J, Rodriquez M, et al.: Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin Infect Dis 1999, 29:199–201.
29. Brueckner RP, Coster T, Wesche DL, et al.: Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 1998, 42:1293–1294.
30. Brueckner RP, Lasseter KC, Lin ET, et al.: First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998, 58:645–649.
31. Walsh DS, Eamsila C, Sasiprapha T, et al.: Randomized, double-blind, placebo controlled evaluation of monthly WR 238605 (TAFENOQUINE) for prophylaxis of Plasmodium falciparum and P. vivax in Royal Thai army soldiers. In Program and abstracts of the 48th annual meeting of the American Society of Tropical Medicine and Hygiene. In Am J Trop Med Hyg 1999, 61(Suppl):502.
32. Shanks GD: Possible options for malaria chemoprophylaxis on the horizon. J Travel Med 1999, 6:S31-S32.
33. Andersen SL, Ager AL, McGreevy P, et al.: Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob Agents Chemother 1994, 38:1862–1863.
34. Anderson SL, Berman J, Kuschner R, et al.: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995, 123:771–773.
35. Andersen SL, Oloo AJ, Gordon DM, et al.: Successful doubleblinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998, 26:146–150.
36. Taylor WR, Richie TL, Fryauff DJ, et al.: Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999, 28:74–81.
37. Heppner DG, Wongsrichanalai C, Walsh DS, et al.: Azithromycin for the prophylaxis of malaria in Thailand. In Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene. In Am J Trop Med Hyg; 1999, 61(Suppl):161.
38. Walsh DS, Looareesuwan S, Wilairatana P, et al.: Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 1999, 180:1282–1287.
39. White NJ: The treatment of malaria. N Engl J Med 1996, 335:800–806.
40. World Health Organization, Division of Control of Tropical Diseases: Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94(Suppl 1):S1-S90. This recent and comprehensive publication provides the World Healh Organization’s recommendations on the management of severe falciparum malaria.
41. Heppner DG, Ballou WR: Malaria in 1998: advances in diagnosis, drug and vaccine development. Curr Treat Opt Infect Dis 1998, 11:519–530.
42. Wesche DL, Schuster BG, Wang WX, Woosley RL: Mechanism of cardiotoxicity of halofantrine [review]. Clin Pharmacol Ther 2000, 67:521–529.
43. Olliaro P, Mussano P: Amodiaquine for treating malaria. Cochrane Database Syst Rev 2000, 2:CD000016.
44. van Dillen J, Custers M, Wensink A, et al.: A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 1999, 93:185–188.
45. Mengesha T, Makonnen E: Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta analysis from six African countries. East Afr Med J 1999, 76:314–319.
46. Cerutti C Jr, Durlacher RR, de Alencar FE, et al.: In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. J Infect Dis 1999, 180(6):2077–2080.
47. Mcintosh HM, Olliaro P: Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database Syst Rev 2000, 2:CD000256.
48. Looareesuwan S, Wilairatana P, Viravan C, et al.: Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997, 56:613–617.
49. Na-Bangchang K, Tippanangkosol P, Ubalee R, et al.: Comparative clinical trial of four regimens of dihydroartemisininmefloquine in multidrug-resistant falciparum malaria. Tropical Med Int Health 1999, 4:602–610.
50. von Seidlein L, Milligan P, Pinder M, et al.: Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated malaria in Gambian children: a double-blind randomized, controlled trial. Lancet 2000, 355:352–357.
51. Genovese RF, Newman DB, Petras JM, Brewer TG: Behavioral and neural toxicity of arteether in rats. Pharmacol Biochem Behav 1998, 60:1–10.
52. Genovese RF, Newman DB, Li Q, et al.: Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 1998, 45:199–202.
53. White NJ: Neurological dysfunction following malaria: Disease-or-drug related. Clin Infect Dis 2000, 30:836.
54. Van Vugt M, Angus BJ, Price RN, et al.: A case-controlled auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 2000, 62:65–69.
55. Sabchaeron A, Attanath P, Chantavanich P, et al.: Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of acute falciparum malaria. Am J Trop Med Hyg 1998, 58:11–16.
56. van Agtmael M, Boucaud O, Malvy D, et al.: The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travelers returning from the Tropics to The Netherlands and France. Int J Antimicrob Agents 1999, 12:159–169.
57. Looareesuwan S, Wilairatana P, Chokejindachai W, et al.: A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999, 60:238–243.
58. von Seidlein L, Bojang K, Jones P, et al.: A randomized, controlled trial of artemether/benflumetol, a new antimalarial, and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg 1998, 58:638–644.
59. Vugt MV, Wilairatana P, Gemperli B, et al.: Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrugresistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999, 60:936–942.
60. Kremser PG, Looareesuwan S, Chulay JD: Atovaquone and proguanil hydrochloride for treatment of malaria. J Travel Med 1999, 6(Suppl 1):S18-S20. The authors discuss the atovaquone and proguanil studies for the treatment of malaria, and have combined and analyzed together the 10 randomized, controlled studies demonstrating the high efficacy of atovaquone-proguanil for the treatment of falciparum malaria in semi-immune and nonimmune populations.
61. TM) and chloroquine. Trans R Soc Trop Med Hyg 2000, 94:77–82.
62. White NJ: What is the future of exchange transfusion in severe malaria? J Infect 1999, 39:185–186.
63. Crawley J, Waruiru C, Mithwani S, et al.: Effect of Phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomized, controlled, intervention study. Lancet 2000, 355:701–706.
64. Baird JK, Basri H, Subianto B, et al.: Treatment of chloroquine resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995, 171:1678–1682.
65. Fryauff DJ, Baird JK, Basri H, et al.: Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. Ann Trop Med Parasitol 1997, 91:7–16.
66. Pukrittayakamee S, Chantra A, Simpson J, et al.: Therapeutic response to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000, 44:1680–1685.
67. Looareesuwan S, Buchachart K, Wilairatana P, et al.: Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 1997, 91:939–943.